STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005%
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Open Angle Glaucoma, Ocular Hypertension
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Trial Timeline
Aug 9, 2022 → Apr 18, 2023
NCT ID
NCT05495061About STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005%
STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005% is a phase 3 stage product being developed by Santen Pharmaceutical for Primary Open Angle Glaucoma, Ocular Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT05495061. Target conditions include Primary Open Angle Glaucoma, Ocular Hypertension.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05495061 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Open Angle Glaucoma, Ocular Hypertension
Other Products from Santen Pharmaceutical
Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77